Recently, the Carbamazepine Extended-Release Tablets (II) developed by Yichang Humanwell Pharmaceutical Co Ltd received the Drug Registration Certificate from the National Medical Products Administration. As a Category III chemical drug, this approval is considered equivalent to passing the generic drug quality and efficacy consistency evaluation, officially granting the drug market authorization in China.

　　This medication is primarily indicated for the treatment of various types of epilepsy, including partial seizures, primary or secondary generalized tonic-clonic seizures, and mixed seizure types. It is also effective in alleviating various forms of nerve pain, such as primary trigeminal neuralgia, primary glossopharyngeal neuralgia, and trigeminal neuralgia associated with multiple sclerosis, providing an effective treatment option for patients with these conditions. Clinical practice has shown that early standardized drug therapy can effectively reduce seizure frequency, alleviate symptoms, and protect the cerebral nerves from ongoing damage.

　　The Carbamazepine Extended-Release Tablets (II) were developed and manufactured in line with international research and production standards, using a “dual filing in China and the U.S.” and “shared production line” approach. Throughout the entire process of research, application, and production, the product simultaneously meets the regulatory requirements of both Chinese and U.S. drug authorities, with the same production system and production line used to satisfy market access standards both domestically and internationally. The drug has obtained approval from the U.S. Food and Drug Administration (FDA) in January 2025, and has now secured the domestic registration certificate as well. (Sanxia Daily: Reporter/Li Tao, Correspondents/Ren Shujuan and Chen Ran)